Background
==========

Perivascular epithelioid cell tumor (PEComa) was first introduced by Zamboni in 1996 to identify a group of mesenchymal neoplasms originating from perivascular epithelioid cells \[[@B1]\]. PEComa family of tumors includes angiomyolipomas (AML), lymphangioleiomyomatosis (LAM), clear cell "sugar" tumor (CCST) of the lung, clear cell myomelanocytic tumor (CCMMT) of the falciform ligament/ligamentum teres and abdominopelvic sarcoma of perivascular epithelioid cells \[[@B2]\]. PEComas other than AML, CCST or LAM are rare. Although increasingly reported over the past decade, PEComas occurring in mesentery are exceedingly rare, with only 6 cases described in the literature so far \[[@B3]-[@B5]\]. The clinical behavior of PEComa is not predictable, and there are no strict histologic criteria for malignancy. Because of its relative rarity, little is known about the natural history and prognostic factors of PEComas, although a stratification of PEComa of soft tissue and genitourinary tract has been recently proposed \[[@B3],[@B6]\]. Herein, we report a PEComa of mesentery of small bowel occurring in a middle-aged female patient with mesenteric lymph node involvement. Although the cytologic appearance of the tumor cells was relatively bland, the presence of extensive necrosis and surrounding tissue invasion were indicative of malignant behavior. To the best of our knowledge, this is the first case of malignant mesentery PEComa with lymph node involvement. The literature on this rare tumor is reviewed and differential diagnosis is discussed.

Case presentation
=================

Clinical presentation and management
------------------------------------

A 38-year-old female patient presented with complaints of abdominal pain and abdominal distension that had persisted 3 days before admission to our hospital. Physical examination showed local tenderness and rebounding pain in the left abdominal region, and decreased bowel sounds. The laboratory results, including blood count, differential, liver and renal function, were within the normal range. There was no fever, weight loss and no palpable lymphadenopathy or organomegaly. A computed tomography (CT) scan showed a poorly circumscribed solid mass (9.9 cm × 8.6 cm × 7.1 cm) with mild heterogeneous enhancement located in the left upper abdominal region with adhesions of wall of jejunum. There was hypointensity areas observed in the mass after gadolinium injection (Figure [1](#F1){ref-type="fig"}). A preoperative presumed diagnosis was extra-gastrointestinal stromal tumor of abdomen. The patient underwent tumor resection and segmental resection of the jejunum. At surgery, the mass was located at the mesentery of the small bowel and a part of the mass was observed to extend to the wall of jejunum. The mass was removed totally, and the postoperative phase was uneventful. Since there was a possibility of tumor metastasis to another anatomical location, the patient was referred to a whole body positron emission tomography (PET)/CT study to search for the potentially secondary tumor, but no abnormality was found. After diagnosis, the patient received 2 courses of chemotherapy with vincristine, ifosfamide, and adriamicin. The patient was on regular follow-up for 6 months after chemotherapy, there was no sign of recurrence of tumor found in this period.

![**Preoperative computed tomography (CT) scan of the mesenteric mass.** Contrast-enhanced CT demonstrating a poorly circumscribed solid mass with mild heterogeneous enhancement located at mesentery and showed adhesions of wall of jejunum. The multiple irregular hypointensity areas were observed in the mass and considered to be necrotic areas (white arrow).](1746-1596-8-60-1){#F1}

Material and methods
====================

On macroscopical examination, the lesion was gray-tan solitary nodular mass with necrotic areas, measuring 10.0 × 8.5 cm, was located in the mesentery of small intestine. The mass was poorly circumscribed and there was no fibrous capsule round the mass. A part of tumor was observed to extend to the wall of jejunum and some enlarged mesenteric lymph nodes were also observed (Figure [2](#F2){ref-type="fig"}). The tumor was routinely fixed in 10% neutral buffered formalin and the tissues were embedded in paraffin. Four micrometer-thick sections were stained with Hematoxylin and Eosin (HE). Immunohistochemical analyses were performed using the ChemMate Envision/HRP Kit (Dako, Glostrup, Denmark). The antibodies used in this study were cytokeratin (AE1/AE3), epithelial membrane antigen (EMA), vimentin, S-100 protein, HMB-45, Melan-A,neuron-specific enolase (NSE), synaptophysin (Syn), chromogranin A (CgA), CD34, CD117, Dog-1, smooth muscle actin (SMA), desmin, Myo-D1, CD68, CD99 and Ki-67.

![**Gross examination of resected mesenteric mass.** The mass was gray-tan solitary nodular mass without a fibrous capsule. The mass was observed to extend to the wall of jejunum and necrotic areas were also found.](1746-1596-8-60-2){#F2}

Pathological findings
---------------------

Under microscopic examination, a part of the tumor was surrounded by a thin fibrous pseudocapsule at the periphery. The tumor was composed of cells with abundant clear to fine eosinophilic granular cytoplasm and round, uniform, nuclei arranged in nests or wide fascicles with delicate vascular septa. Most of tumor cells appeared to have bland cytologic features. However, in some areas, the cells became more epithelioid, and nuclei varied in size and shape, with dispersed chromatin and prominent nucleoli. Mitoses were present with mitotic rate of 2/50 high power fields. There was extensive coagulative necrosis and hemorrhage but neither adipocytes nor thick-walled blood vessels were observed in the tumor. The tumor cells appeared to have infiltrated into the underlying smooth muscle of jejunum but there were no features of vascular invasion. One of enlarged lymph nodes of mesentery was found to be involved by tumor (Figure [3](#F3){ref-type="fig"}A-D). Immunohistochemically, the tumor cells were stained positive for HMB-45, Melan-A, NSE, CD68 and calponin (focal and weakly), but were negative for S-100 protein, Syn, CgA, cytokeratin (AE1/AE3), EMA, CD34, CD117, Dog-1, SMA, desmin, Myo-D1 and CD99. Ki-67 was positive in 3% of tumor cells (Figure [3](#F3){ref-type="fig"}E-F). Based on the pathological findings, the mesenteric mass was diagnosed as malignant perivascular epithelioid cell tumor with lymph node involvement.

![**Photomicrographs of the mesenteric mass.** (**A**) At lower power field, the tumor was observed to be composed of epithelioid tumor cells with clear to eosinophilic cytoplasms. The epithelioid tumor cells were arranged around delicate vasculature. (**B**) The epithelioid tumor cells had round to oval vesicular nuclei with 1-2 centrally located small nucleoli, and mitotic figure was observed in the tumor cells (black arrow). (**C**) Extensive necrotic areas were observed in the tumor. Note the atypical tumor cells with irregular hyperchromatic nuclei at the periphery of necrosis. (**D**) One of enlarged mesenteric lymph nodes was observed to be involved by tumor cells. Immunohistochemical analysis of the mesenteric mass showed epithelioid tumor cells were diffusely positive for melanocytic markers, HMB-45 (**E**) and Melan-A (**F**). (**A** and **C**, H&E staining with original magnification × 200; **B**, H&E staining with original magnification × 400; **D**, H&E staining with original magnification × 100; **E**-**F**, Immunohistochemical staining with original magnification, ×400).](1746-1596-8-60-3){#F3}

Conclusions
===========

Perivascular epithelioid cell tumor (PEComa) is a mesenchymal tumor composed chiefly of perivascular epithelioid cell (PEC). PEC was first described in 1994 by Bonetti et al. to introduce the concept of a family of tumor that was characterized by the presence of a peculiar muscle cell that expressed melanoma-associated antigens such as HMB-45 and HMSA-1 \[[@B7]\]. The term PEComa was coined by Zamboni et al. in 1996 to describe this rare family of lesions \[[@B1]\]. In 2002, the World Health Organization accepted the designation PEComa as a distinct mesenchymal neoplasm composed of histologically and immunohistochemically unique PECs \[[@B8]\]. The histogenesis and cytogenetics of PEComa are largely unknown. Until recently, there has been no known normal counterpart of PEC. Bonnetti et al. hypothesized that PEC can modulate its morphology and immunophenotype. They believe that the PEComa is composed of PECs in different stages of modulation with consistent reactivity for melanoma-associated markers, variable reactivity for muscular markers, and nonreactivity for epithelial markers \[[@B7]\]. Although a few researchers still doubt the existence of this entity due to the overlapping morphologic and immunologic features with smooth muscle tumors and the absence of a normal counterpart for PEC, the increasing genetic evidence has shown PEComa to be a distinct type of neoplasm \[[@B9],[@B10]\].

PEComas have been found in various organs and have a tendency to affect women with approximately 40% of tumors originated from the uterus \[[@B2]\], although some unusual sites can be also involved occasionally, such as vagina \[[@B11]\], orbit \[[@B12]\], small and large bowel \[[@B13]\], heart \[[@B14]\] prostate \[[@B15]\], bladder \[[@B16]\] and endometrium \[[@B17]\]. Multifocal PEComas (PEComatosis) have been described in the literature \[[@B18]\]. Mesenteric PEComas are rare with only 6 cases described in the literature so far \[[@B3]-[@B5]\] (Table [1](#T1){ref-type="table"}). The ratio of mesenteric PEComa incidence in women and men is 2:1. 4 of 6 cases were considered to be malignant PEComa with tissue invasion and the tumors recurred within 6-22 months, although two cases received concurrent chemoradiotherapy after surgical resection. None of previously reported mesenteric PEComas has lymph node involvement. To our best knowledge, our presenting case is the first one of mesenteric malignant PEComa with lymph node involvement, although the cytologic appearance of tumor cells is relatively bland.

###### 

Clinicopathological features of mesenteric PEComas described in present and previous reports

   **No.**       **Authors (yr.)**        **Diagnosis**     **Age (year)/Gender**   **Tumor size (cm)**   **Nuclear grade**   **Cellularity**   **MF (per 50HPF)**          **Invasion**           **Necrosis**   **LN status**   **Treatment**                          **Outcome**
  --------- --------------------------- ------------------ ----------------------- --------------------- ------------------- ----------------- -------------------- ----------------------------- -------------- --------------- --------------- -----------------------------------------------------------
      1      Folpe AL (2005) \[[@B3]\]   PEComa with UMP          67/Female                13.0                 High             Moderate               0                        No                     No        Not involved       SE only                          NED at 84 months
      2                                   Benign PEComa           97/Female                 4.0             Intermediate         Moderate               0                        No                     No        Not involved       SE only                          NED at 38 months
      3                                  Malignant PEComa         80/Female                 9.5                 High               High                \>50               Vascular invasion            Yes        Not involved       SE only                          NED at 19 months
      4                                  Malignant PEComa         46/Female                12.0             Intermediate         Moderate               5                 Vascular invasion            Yes        Not involved       SE + CT      Recur and liver metastases at 22 months; die at 27 months
      5      Gross E (2010) \[[@B4]\]    Malignant PEComa         5.5/Male                  5.0                 High             Moderate               NA           Surrounding tissue invasion        No        Not involved       SE only                          NED at 24 months
      6       Lai CL (2012) \[[@B5]\]    Malignant PEComa          59/Male                 11.0                 High               High                 3                 Vascular invasion            Yes        Not involved       SE + CT                      Recur at 6 months; alive
      7          The present case        Malignant PEComa         38/Female                10.0             Intermediate         Moderate               2            Surrounding tissue invasion       Yes          Involved         SE + CT                           NED at 6 months

UMP, uncertain malignant potential; MF, mitotic figure; LN, lymph node; SE, surgical excision; CT, chemotherapy; NA, not available; NED, no evidence of disease.

Due to their rarity, the criteria for the diagnosis of malignancy have not yet been fully established. Some types of PEComa family, such as AML and epithelioid AML of kidney, have been infrequently reported to have metastasis to lymph nodes or extra-renal sites, but regional lymph node involvement and vascular invasion were considered to represent a multifocal growth pattern rather than metastasis \[[@B19]\]. Among adverse pathologic parameters in AMLs, including cellularity, high nuclear grade and mitotic figures, none correlate with outcome, although tumors with necrosis, mitotic activity, nuclear anaplasia and extra-renal spread should raise significant concern for malignant outcome. In fact, we are not sure the lymph node involvement of the current case representing a multifocal growth pattern or metastasis so far. Folpe et al. proposed provisional criteria for PEComas of soft tissue and gynecoelogic origin in 2005 \[[@B3]\]. In these diagnostic criteria, PEComas were classified into "benign," "of uncertain malignant potential," and "malignant" categories. There were 6 histological features indicative of high risk: tumor size \>5 cm, infiltrative pattern, high nuclear grade and cellularity, high mitotic rate (\>1/50 HPF), necrosis, and vascular invasion. Small PEComas (\<5 cm) without any of the 6 high-risk features were most likely to be benign. Large PEComas (\>5 cm) without any other features had uncertain malignant potential. PEComas with 2 or more high-risk features should be considered malignant. In 2008, Fadare et al. suggested that the only features that indicate a definite potential for aggressive behavior were a mitotic count \>1/10 HPF and/or coagulative necrosis, while cytologic atypia should be considered to be at least an indication of uncertain malignant potential. The size of tumors was not advised to distinguish malignancy or non-malignant PEComas \[[@B6]\]. The regional lymph node involvement was not considered to be a worrisome histologic feature in both criteria. The present case was considered to be a malignant PEComa, because the tumor had the most of worrisome histologic features presented either by Folpe or by Fadare. However, it has revealed that malignant PEComa with frankly unfavorable morphological features have an indolent clinical course even in the presence of lymph node involvement \[[@B20]\]. Recent studies have also demonstrated that random X chromosome inactivation could be detected in various involved lymph nodes, supporting the hypothesis of a multifocal disease rather than a metastatic tendency \[[@B20]\]. Due to the limited case numbers and the short follow-up period, we could not define prognostic factors for malignant PEComa. However, combined with previously reported PEComas with malignant features \[[@B4],[@B5],[@B15],[@B20],[@B21]\], we consider that malignant PEComas should be highly aggressive in biological behavior. Therefore, infiltrating growth pattern and extensive coagulative necrosis should be more important factors to be used for malignant evaluation because they represent the aggressiveness in biological behavior of this tumor. Hypercellularity, high or atypical mitotic figures, and even regional lymph node involvement might not indicate the overt malignancy of this tumor.

The microscopic morphology of the present case was characterized by epithelioid tumor cells with abundant clear cytoplasm arranged in nests or wide fascicles with delicate vascular septa. These morphological appearances may pose a diagnostic dilemma, especially in unusual locations. A differential diagnosis of PEComa in soft tissue usually includes clear-cell sarcoma of soft tissue (also known as "malignant melanoma of soft parts"), alveolar soft part sarcoma and epithelioid leiomyosarcoma. However, PEComas differential diagnosis in the mesentery should mainly include epithelioid leiomyosarcoma, epithelioid extra-gastrointestinal stromal tumor (extra-GIST) and metastatic clear-cell renal cell carcinoma. Although PEComas and clear-cell sarcoma of soft tissue share some phenotypic features, including positive reactivity to the melanocytic marker HMB-45 and Melan-A, clear-cell sarcoma of soft tissue exhibits dense fibrous septae rather than the delicate vascular-rich stroma of the PEComas. In addition, clear-cell sarcoma of soft tissue always shows S-100 protein positivity, which is usually absent in PEComa. Alveolar soft part sarcoma is a rare tumor composed of large, uniform, epithelioid cells having abundant eosinophilic, granular cytoplasm arranged in solid nests and/or alveolar structures, separated by thin, sinusoidal vessels, which may cause diagnostic confusion with PEComas. However, alveolar soft part sarcoma has no consistently immuno-positive findings, particularly it is negative for melanocytic markers. Epithelioid leiomyosarcoma may share histologic features of PEComas: both tumors are composed of spindle and/or epithelioid cells with variable reactivity for smooth muscle markers, such as SMA, calponin and H-caldesmon. However, leiomyosarcomas show negative staining for melanocytic markers. In addition, PEComa is readily differentiated from epithelioid extra-GIST and metastatic clear-cell renal cell carcinoma by positive immunohistochemical staining for Melan-A and HMB-45 and negative staining for both CD117, Dog-1, CD34 and pan-cytokeratin (AE1/AE3).

Effective therapies for PEComas have yet to be established and the management of PEComas is quite variable. Surgical excision is the most common approach for PEComa but adjuvant chemo- or radio-therapy, even hormone therapy has also been advised for all patients with malignant features. However, due to the rarity of the disease and the difficulty in predicting the malignant behavior, the benefit of those adjuvant therapies is still questionable. In our case, the patient received 2 courses of chemotherapy after surgery, and there was no sign of recurrence of tumor found in short follow-up period. However, close clinical surveillance accompanied by imaging examination should be recommended to inspect the local recurrence and distant metastasis of this tumor.

In conclusion, we reported herein an unusual case of mesenteric PEComa occurring in a middle-aged patient with regional lymph node involvement. Although the cytologic appearance of tumor cells was relatively bland, the infiltrating growth pattern and extensive coagulative necrosis should be indicative malignancy. We consider that marked hypercellularity, active mitotic figures, and even regional lymph node involvement observed merely in tumor might not represent a distinctive sign of malignant PEComa. However, this postulate should be further investigated by more such cases with long-term follow up.
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